Saturday, December 21, 2024

Investing in Hope: Why Cancer Therapy is the Sector You Can’t Ignore

Date:

All investors should definitely have quality investment in the Cancer therapy sector either directly or as a proxy.

Very simply. The goal of cancer treatment is to cure or shrink a cancer or stop it from spreading. Hard to make a solid case to not own some. Many cancer treatments exist. Your cancer treatment plan may be based on your type of cancer and your situation. Today, Aprea Therapeutics is a clinical stage, platform biotechnology company focused on the development of novel, synthetic lethality-based therapies with direct on-target mechanisms of action and clear clinical pathways.  ‘Lethality’ is such a great word when attempting to cure CancerGlobal Cancer Therapeutics Market size was valued at USD 136.6 Billion in 2022 and is poised to grow from USD 149.02 Billion in 2023 to USD 299.13 Billion by 2031, at a CAGR of 9.1% during the forecast period (2024-2031).

As one can see the chart above denotes a steady market that says accumulation with slight profit taking is underway. 

According to Precedence Research, the global digital therapeutics market size was estimated at USD 7.88 billion in 2024 and is expected to hit around USD 56.76 billion by 2034, poised to grow at a CAGR of 21.83% from 2024 to 2034. North America contributed the largest market share of 44.03% in 2023. (2 days ago.)

Currently at USD3.20, Analysts predict increases in the neighbourhood of;

Key Level #1: $4.34 (+33.54%)

Key Level #2: $4.99 (+53.54%)

Key Level #3: $6.83 (+110.15%)

Key Level #4: $7.74 (+138.15%)

Potential Support: $2.73

52-week hi-lo.

52 Week hi-lo is USD8.50 to USD3.50. Even the frequent price pops should intrigue traders. This story and Company are the very embodiment of a dollar cost average. Besides maintaining exposure, investor with be there for natural growth, the M&A sector, and simply a way to keep apprised amend new cutting-edge therapies.

The life you save through your investment could be you own.

Or Mine.

Bob Beaty
+ posts

For over 30 years, Bob Beaty has been explaining concepts and companies to the global investment community. One of the original writers for Jim Cramer’s Thestreet.com, he also wrote for AOL (Can/US), the Globe and Mail, and the Huffington Post. Over that period, he illuminated small-cap companies to investors with wit and pith but mostly opinion and facts. Investing should be fun. Pedantic, staid content is no fun.

Before embarking on his writing career, Bob had a successful international journey in the finance industry. He served as a broker, derivatives product manager, and a Director of London's Credit Suisse subsidiary. His career spanned across major financial hubs including Toronto, Vancouver, and the UK, giving him a unique global perspective. (He is still fondly remembering those English client lunches.)

Other than everything Groucho Marx and George Carlin ever said, Bob lives by a simple credo;

‘Never do anything the person standing in front of you can't understand.’ Hunter S. Thompson.

Let’s go.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Share post:

Subscribe

spot_img

Popular

More like this
Related

APRE vs. KPTI: Which Stock is the Best Choice? 

Aprea Therapeutics, Inc. (NASDAQ: APRE) and Karyopharm Therapeutics Inc....

Why Thumzup is the Next Big Thing in the $700 Billion Digital Ad Market

Thumzup Media Corporation ("Thumzup" or TZUP or the "Company") (Nasdaq:),...

Stocks to Watch Today on 12/19

Dollar Tree's Leadership Shake-Up Dollar Tree is undergoing a major...

6 Biotech Companies to Watch

The biotechnology sector is home to some of the...